Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Veracyte, Inc. - Common Stock
(NQ:
VCYT
)
44.19
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Veracyte, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
September 29, 2026
First predictive evidence in intermediate-risk prostate cancer supporting use of the Decipher test to guide short-term hormone therapy decisions to be presented at ASTRO 2026
From
Veracyte, Inc.
Via
GlobeNewswire
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
September 25, 2026
Six oral presentations and two posters will highlight Decipher’s prognostic and predictive value in identifying patients’ risk of progression and likelihood of benefiting from treatment...
From
Veracyte, Inc.
Via
GlobeNewswire
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
September 14, 2026
Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey
From
Veracyte, Inc.
Via
GlobeNewswire
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
September 01, 2026
From
Veracyte, Inc.
Via
GlobeNewswire
Veracyte Announces Second Quarter 2026 Financial Results
July 30, 2026
From
Veracyte, Inc.
Via
GlobeNewswire
Veracyte to Participate in Upcoming Investor Conferences
July 28, 2026
From
Veracyte, Inc.
Via
GlobeNewswire
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
July 09, 2026
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
June 01, 2026
From
Veracyte
Via
Business Wire
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
May 30, 2026
From
Veracyte, Inc.
Via
Business Wire
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
May 29, 2026
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
May 22, 2026
From
Veracyte, Inc.
Via
Business Wire
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
May 21, 2026
From
Veracyte
Via
Business Wire
Veracyte to Participate in Upcoming Investor Conferences
May 19, 2026
From
Veracyte, Inc.
Via
Business Wire
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
May 15, 2026
From
Veracyte, Inc.
Via
Business Wire
A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech
May 13, 2026
Issued on behalf of VentriPoint Diagnostics Ltd.
From
USA News Group
Via
GlobeNewswire
Veracyte Announces First Quarter 2026 Financial Results
May 05, 2026
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
April 28, 2026
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
April 14, 2026
From
Veracyte, Inc.
Via
Business Wire
Veracyte Names Kevin Haas as Chief Development and Technology Officer
March 16, 2026
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
February 25, 2026
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
February 24, 2026
From
Veracyte
Via
Business Wire
Veracyte to Participate in Upcoming Investor Conferences
February 19, 2026
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
February 04, 2026
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
January 11, 2026
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 29, 2025
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in Upcoming Investor Conferences
November 06, 2025
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Third Quarter 2025 Financial Results
November 04, 2025
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
October 15, 2025
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
November 03, 2025
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
September 28, 2025
From
Veracyte, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
